Tugce Uzar

Tugce Uzar

Auto-generated profile, based on publicly available information

Tugce Uzar

University of Health Sciences, Umraniye Training and Research Hospital, Department of Otolaryngology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Radiology Case Reports
Verified
Journal Article
Open access
TUTugce Uzar
Tugce Uzar
ITIrem Turkmen
Irem Turkmen
EMElif Berber Menekse
Elif Berber Menekse
ADAdem Dirican
Adem Dirican
PEPankina Ekaterina
Pankina Ekaterina
SOSevket Ozkaya
Sevket Ozkaya
Deep dry needling is an evidence-based treatment technique that is accepted and used by physical therapists for treatment of musculoskeletal pain. We present a case of iatrogenic pneumothorax due to deep dry needling over the posterior thorax. A 36-year old presented with right chest pain 2 hours after dry needling for pain in his back muscles. Chest radiograph suggested small right pneumothorax and the finding was confirmed by computed tomography. Not only should practitioners and their patients be aware of potential complications of dry needling, but also physicians who might see patients with complications.

31 May 2023 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
YDYaşar Kemal Duymaz
Yaşar Kemal Duymaz
ŞŞŞamil Şahin
Şamil Şahin
BEBurak Erkmen
Burak Erkmen
TUTuğçe Uzar
Tuğçe Uzar
SOSerap Sahin Onder
Serap Sahin Onder

1 January 2019 in Journal of Cardiology Case Reports
Verified
Journal Article
Open access
TUTugce Uzar
Tugce Uzar
KEKursat Erkaya
Kursat Erkaya
UAUtku Arslan
Utku Arslan
AAAli E Atas
Ali E Atas
PEPankina Ekaterina
Pankina Ekaterina
SOSevket Ozkaya
Sevket Ozkaya

14 January 2020 in Current Epidemiology Reports
Verified
Journal Article
Closed access
PDF file
EAElif Ari
Elif Ari
TUTugce Uzar
Tugce Uzar
SESena Eksi
Sena Eksi

31 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ADAdem Dirican
Adem Dirican
TUTugce Uzar
Tugce Uzar
IKIrem Karaman
Irem Karaman
AUAziz Uluisik
Aziz Uluisik
SOSevket Ozkaya
Sevket Ozkaya
Background: During the current pandemic, a great effort is made to understand the COVID-19 and find an effective treatment. As of 17 August 2020, there is no specific drug or biologic agent which have been approved by the FDA for the prevention or treatment of COVID-19. Methods: We retrospectively analyzed the clinical and radiological findings of 211 COVID-19 in-patients that were treated between March - August 2020. Confirmation of a COVID-19 diagnosis was made according to a positive RT-PCR result with a consistent high-resolution-CT (HRCT) finding. Radiological images and the rate of clinical response of patients were investigated. Result: While 128 patients (58.7) did not develop pneumonia, the mild, moderate and severe pneumonia ratios were 28(13.2%), 31(18.7%) and 27(22.9%). 72 patients (34.1%) whose PCR tests were positive did not show any symptom and they were followed in isolation without treatment. 52 patients (24.6%) received hydroxychloroquine plus azithromycin, 57 patients (27%) received favipiravir and 30 patients (14.2%) received favipiravir plus dexamethasone as the first line of treatment. 63.1% of pneumonia patients who received hydroxychloroquine plus azithyromycine, 28.3% of patients who received favipiravir and 10% of patients who received favipiravir plus dexamethasone showed a failure of treatment. Conclusion: The pulmonary infiltrates of COVID-19 are not infective; therefore, the characteristic of the disease should be described as COVID-19 pneumonitis instead of pneumonia. The favipiravir plus dexamethasone seems to be the only drug combination to achieve the improvement of radiological presentation and clinical symptoms in COVID-19 pneumonia patients.